These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24448976)

  • 1. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
    Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
    Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
    Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging roles of Interleukin-34 together with receptor activator of nuclear factor-kB ligand and osteoprotegerin levels in periodontal disease.
    Bozkurt Doğan Ş; Öngöz Dede F; Ballı U; Sertoğlu E
    Cytokine; 2021 Aug; 144():155584. PubMed ID: 34034144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
    Mountzios G; Terpos E; Syrigos K; Papadimitriou C; Papadopoulos G; Bamias A; Mavrikakis M; Dimopoulos MA
    Transl Res; 2010 May; 155(5):247-55. PubMed ID: 20403580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indication of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) in gingival crevicular fluid to remodeling of alveolar bone during retention].
    Zhao NN; Lin JX; Chen ZB; Liu Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):108-12. PubMed ID: 22353912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, TWEAK, RANKL and OPG.
    Yakar N; Guncu GN; Akman AC; Pınar A; Karabulut E; Nohutcu RM
    Cytokine; 2019 Jan; 113():433-439. PubMed ID: 30377055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
    Mozzati M; Martinasso G; Maggiora M; Scoletta M; Zambelli M; Carossa S; Oraldi M; Muzio G; Canuto RA
    Clin Oral Investig; 2013 May; 17(4):1259-66. PubMed ID: 22864527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.
    Martini G; Gozzetti A; Gennari L; Avanzati A; Nuti R; Lauria F
    Haematologica; 2006 Dec; 91(12):1720-1. PubMed ID: 17145616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis.
    Özden FO; Sakallioğlu EE; Demir E; Bilgici B; Tunçel ÖK; Gökosmanoğlu F; Atmaca A
    J Oral Sci; 2017; 59(1):147-155. PubMed ID: 28367895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between T-helper cell polarization and the RANKL/OPG ratio in gingival tissues from chronic periodontitis patients.
    Bi CS; Sun LJ; Qu HL; Chen F; Tian BM; Chen FM
    Clin Exp Dent Res; 2019 Aug; 5(4):377-388. PubMed ID: 31944625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of leukocyte-platelet-rich fibrin (L-PRF) on the rate of orthodontic tooth movement and expression of various biomarkers in gingival crevicular fluid.
    Krishna V B; Duggal I; Sharan J; Mangaraj M; Duggal R; Jena AK
    Clin Oral Investig; 2023 May; 27(5):2311-2319. PubMed ID: 37079155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total oxidant status and bone resorption biomarkers in serum and gingival crevicular fluid of patients with periodontitis.
    Baltacıoğlu E; Kehribar MA; Yuva P; Alver A; Atagün OS; Karabulut E; Akalın FA
    J Periodontol; 2014 Feb; 85(2):317-26. PubMed ID: 23701481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio.
    Bostanci N; Ilgenli T; Emingil G; Afacan B; Han B; Töz H; Atilla G; Hughes FJ; Belibasakis GN
    J Clin Periodontol; 2007 May; 34(5):370-6. PubMed ID: 17355365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of RANKL and osteoprotegerin levels in the gingival crevicular fluid of young cigarette- and waterpipe-smokers and individuals using electronic nicotine delivery systems.
    Ibraheem WI; Fageeh HI; Preethanath RS; Alzahrani FA; Al-Zawawi AS; Divakar DD; Al-Kheraif AA
    Arch Oral Biol; 2020 Jul; 115():104714. PubMed ID: 32442729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis.
    Mogi M; Otogoto J; Ota N; Togari A
    J Dent Res; 2004 Feb; 83(2):166-9. PubMed ID: 14742657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis.
    Verde ME; Bermejo D; Gruppi A; Grenón M
    Acta Odontol Latinoam; 2015 Dec; 28(3):215-21. PubMed ID: 27095621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid.
    Bostanci N; Saygan B; Emingil G; Atilla G; Belibasakis GN
    J Clin Periodontol; 2011 May; 38(5):428-33. PubMed ID: 21261673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.